Related Experiment Video
Updated: Jul 14, 2026
07:03
Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration
Published on: May 4, 2017
CD14, endotoxin, and asthma risk: actions and interactions
1Arizona Respiratory Center, University of Arizona, 1501 N. Campbell Avenue, Ste. #2349, P.O. Box 245030, Tucson, AZ 85724, USA. fernando@arc.arizona.edu
Proceedings of the American Thoracic Society
|July 4, 2007
Summary
The CD14/-159 gene variant
Area of Science:
- Genetics
- Environmental Health
- Immunology
Background:
- The CD14/-159 single nucleotide polymorphism (SNP) is frequently studied in relation to asthma.
- Previous studies on CD14/-159 and asthma show inconsistent and heterogeneous results.
- Gene-environment interactions are increasingly recognized as crucial in complex diseases.
Purpose of the Study:
- To investigate the role of the CD14/-159 SNP in asthma and allergic phenotypes.
- To explore gene-environment interactions, specifically with microbial exposures, in asthma development.
- To understand the heterogeneity in genetic association studies of asthma.
Main Methods:
- Analysis of the CD14/-159 SNP in genetic association studies.
- Assessment of environmental exposures, including house-dust endotoxin and domestic microbial sources.
- Examination of gene-environment interactions with allergic phenotypes and asthma outcomes.
Main Results:
- A significant gene-environment interaction was observed between CD14/-159 genotype and microbial exposure levels.
- The C-allele confers risk for allergic phenotypes at low microbial exposure.
- The T-allele confers risk for allergic phenotypes at high microbial exposure.
- Homozygotes for the C-allele exhibit a stronger protective effect from microbial exposure against allergic outcomes.
Conclusions:
- The CD14/-159 SNP's association with asthma is dependent on environmental microbial exposure levels.
- Gene-environment interactions, particularly with microbial factors, are critical for understanding asthma pathogenesis.
- The heterogeneity in previous genetic studies may be attributed to unassessed gene-environment interactions.
Related Concept Videos
01:29Asthma-I: Introduction
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
01:28Asthma I: Introduction
Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:30Asthma-IV: Diagnostic and Management
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:26Asthma-II: Pathophysiology and Classification
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include: